Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies

New York, New York--(Newsfile Corp. - March 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence Biomed" or the "Company") today announced that it has expanded and further strengthened its Scientific Advisory Board (SAB) with the appointment of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology. He is the Professor and Chair of the Dept of Psychiatry and Mental Health at the University of Cape Town (UCT) and Director of the South African Medical Research Council (MRC) Unit on Risk & Resilience in Mental Disorders. Dr. Stein joins Dr. Albert Garcia-Romeu (Chair), Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Dr. Seth Feuerstein, Department of Psychiatry at Yale University, and Dr. Clive Ward-Able, Medical Director of Psyence Biomedical on the Company's SAB. The Company will discuss the role of the SAB in a corporate webinar scheduled for Thursday, April 10, 2025, at 12:00 p.m. EST.

"Dr. Stein brings decades of diverse clinical and scientific experience in the area of psychopharmacology and psychotherapy trials, and I could not be more excited to welcome him to our SAB," stated Dr. Neil Maresky, M.B.,B.Ch., Chief Executive Officer of Psyence Biomed. "While we continue in our Phase IIb clinical trial of psilocybin as a potential treatment for Adjustment Disorder in Palliative Care, we will also be advancing plans for our second development indication in Alcohol Use Disorder. With the objective guidance from our world-class SAB, I believe we are well positioned to introduce an entirely new class of psilocybin-based therapeutics to address significant unmet needs in mental health and addiction."

"Psychedelic therapies hold promise in psychiatry across a number of indications," stated Dr. Stein. "I am excited to join Psyence Biomed's SAB at this crucial time for the company and help guide their pioneering work with nature-derived psilocybin. I look forward to working alongside my fellow SAB members as Psyence Biomed advances and expands its pipeline of promising psilocybin-based therapeutic candidates."

Dr. Dan J. Stein is internationally recognized as an expert in psychopharmacology. He completed his fellowship and residency training at Columbia University and the New York State Psychiatric Institute. He is a clinician-scientist whose work has long focused on anxiety and related disorders, including obsessive-compulsive spectrum conditions and posttraumatic stress disorder. He has also mentored a range of other research, with publications spanning basic neuroscience, through clinical research, and on to public mental health. His research has had considerable influence (as evidenced by a Google h-index > 200), as has his mentorship (as evidenced by the career success of his postgraduate students and fellows). Awards for his work include the International College of Neuropsychopharmacologicum's Max Hamilton Award for his contributions to psychopharmacology, and its Ethics in Psychopharmacology Award.

Corporate Webinar

Psyence Biomed is pleased to announce that it will be hosting a corporate webinar with its executive team on Thursday, April 10, 2025, at 12:00 PM EST. This webinar will provide investors and stakeholders with a unique opportunity to engage directly with Psyence Biomed's leadership, ask questions, and gain valuable insights into the Company's ongoing clinical research and future initiatives. During the webinar, the executive team will also discuss the Company's broader vision for the future of psychedelic therapeutics. Investors and stakeholders are encouraged to attend and participate in this informative session.

To register, please access the following link: Psyence Biomed Corporate Webinar

About Psyence Biomed:

Psyence Biomedical Ltd. (NASDAQ: PBM) is one of the few vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. Psyence is dedicated to addressing unmet mental health needs, particularly in palliative care. The name 'Psyence' merges 'psychedelics' and 'science,' reflecting the company's commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.

Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning.

Forward-looking statements in this communication include statements regarding the progress of the Phase IIb clinical trial and preparations for the Company's second development indication. These forward-looking statements are based on a number of assumptions, including the assumption that there will be no delays in the execution of the Phase IIb clinical trial implementation schedule and that topline data from this trial will be positive. There can be no assurance that the Company will continue to maintain compliance with Nasdaq's continued listing requirements.

There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others: (i) delays in the execution of the Phase IIb trial; (ii) the ability of Psyence Biomed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence Biomed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence Biomed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence Biomed's business and changes in Psyence Biomed's capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the Company's final prospectus (File No. 333-284444) filed with the Securities and Exchange Commission (the "SEC") on January 24, 2025 and other documents filed by Psyence Biomed from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such information. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence Biomed does not intend to update these forward-looking statements.

The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244867